SecBot SecBot

ZNTL

Zentalis Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· CIK 0001725160 Biotech & Drug Discovery
$1.60 −0.10 (−5.88%)
Nov 16 4:00 PM ET · prev $1.70
Market cap
$165.1M
Micro cap
Consensus
Buy
76% Buy or better · 17 analysts
Median target
$7.00
+337% · range $5.00–10.00
1 year
+21.2%
from $1.32 · Nov 17
30 days
−30.4%
from $2.30
52-week range
$1.30–6.61
−76% from high · low Nov 20
Avg volume 20D
1.41M
shares / day
Short interest
5.04M
≈5.3% of shares · −15.9%
Days to cover
3.5
at average volume
Insider net
+$15.0M
1 buyer · 3 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $15.2M at an average $3.50. 3 insiders sold $134.7K. Price is 54% below their cost.

  • InstitutionsMIXED

    Q3 2026: 15 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    13 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.490 → −$0.519 over 90 days. 2 up, 1 down in 30 days.

  • Short sellersCOVERING

    Short interest −15.9% to 5.04M shares. 3.5 days to cover, ≈5.3% of shares.

  • TrendDOWNTREND

    36% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD PORTFOLIO MANAGEMENT LLCADD1,271,708$3.5M
Qube Research & Technologies LtdADD1,135,037$3.1M
STATE STREET CORPADD1,110,357$3.1M
JPMORGAN CHASE & CODOUBLED951,147$2.6M
DIMENSIONAL FUND ADVISORS LPADD706,231$2.0M
FMR LLCDOUBLED677,721$1.9M
MARSHALL WACE, LLPTRIM426,889$1.2M
Squarepoint Ops LLCDOUBLED255,024$706.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 76% rate it Buy or better
Strong Buy7Buy6Hold4Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +337%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Wedbush
UPGRADE
UPGRADEOutperform
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 16, 2026William Blair
INITIATE
INITIATEOutperform
Jul 23, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
Jul 17, 2026Mizuho
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$15.2M
bought · 1 insider
$134.7K
sold · 3 insiders
−54.3%
vs their $3.50 cost
DateInsiderTypeValue
Sep 30, 2026
Bruns Ingmar
Chief Medical Officer
Sep 30, 2026
AWARD$21.2K
Aug 14, 2026
WALTERS GROUP
10%+ Owner
Aug 14, 2026
BUY$15.2M
Jun 16, 2026
Myers Scott Dunseth
Director
Jun 16, 2026
AWARD57,100 sh
Jun 16, 2026
Skvarka Jan
Director
Jun 16, 2026
AWARD57,100 sh
Jun 16, 2026
Kariuki Enoch
Director
Jun 16, 2026
AWARD57,100 sh
Jun 16, 2026
Walker Luke Nathaniel
Director
Jun 16, 2026
AWARD57,100 sh
Jun 16, 2026
Johnson David Michael
Director
Jun 16, 2026
AWARD57,100 sh
May 26, 2026
Campbell Shannon
Director
May 26, 2026
AWARD114,200 sh

Earnings setup

Estimates
−$0.38
EPS estimate, this quarter
−6%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.38-$0.45–-$0.25+10.1%$0.00
Next Q-$0.48-$0.63–-$0.40+22.6%$133.3K
Current FY-$1.75-$1.86–-$1.50+13.0%$0.00
Next FY-$1.52-$1.90–-$1.06+16.2%$1.6M

Short side

FINRA· Oct 30, 2026
5,036,334
shares short
-15.9%
vs prior settlement
3.5
days to cover
≈5.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 9, 2026
Earnings result
ZNTL Q3 2026 Earnings: EPS $-0.34 (+37.9% vs est)
Nov 3, 2026
Press release
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage…
Nov 2, 2026
Press release
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage…
Oct 18, 2026
FDA
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to…
Oct 1, 2026
Activist
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage…

SecBot reports

11 filings · 7 press releases · 6 bullish · 2 bearish · 1 mixed · 2 neutral
All ZNTL filing & press-release reports (18)